Stockscreener 앱 받기
2.04%
시간 외 거래:
전일 마감가:
$2.94
열려 있는:
$2.94
하루 거래량:
4.03M
Relative Volume:
0.99
시가총액:
$583.55M
수익:
$36,000
순이익/손실:
$-91.08M
주가수익비율:
-3.1997
EPS:
-0.9376
순현금흐름:
$-71.67M
1주 성능:
-1.64%
1개월 성능:
+4.53%
6개월 성능:
-33.33%
1년 성능:
-17.36%
1일 변동 폭
$2.90
$3.02
1주일 범위
$2.84
$3.20
52주 변동 폭
$2.56
$6.4399
알티뮨 Stock (ALT) Company Profile
명칭
Altimmune Inc
전화
(240) 654-1450
주소
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.00 | 571.88M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
알티뮨 Stock (ALT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 업그레이드 | Goldman | Sell → Neutral |
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-07-10 | 재개 | Goldman | Sell |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2025-01-08 | 개시 | Stifel | Buy |
| 2024-11-12 | 개시 | UBS | Buy |
| 2024-04-29 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-24 | 개시 | Goldman | Neutral |
| 2023-03-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-02 | 개시 | H.C. Wainwright | Buy |
| 2021-02-11 | 개시 | Guggenheim | Buy |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-11-12 | 재확인 | B. Riley Securities | Buy |
| 2020-09-25 | 개시 | B. Riley FBR | Buy |
| 2020-08-14 | 개시 | Evercore ISI | Outperform |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-07-28 | 개시 | JMP Securities | Mkt Outperform |
| 2020-02-24 | 재개 | ROTH Capital | Buy |
| 2019-07-19 | 개시 | ROTH Capital | Buy |
| 2017-10-09 | 개시 | Piper Jaffray | Overweight |
모두보기
알티뮨 주식(ALT)의 최신 뉴스
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:2.940|Chg%:+0.060 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - news.alphastreet.com
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Altimmune Q2 EPS $(0.12) beats $(0.15) estimate - scanx.trade
Earnings call transcript: Altimmune tops Q2 2026 EPS view as shares rise - Investing.com Australia
Altimmune Q2 Earnings Call Highlights - MarketBeat
Altimmune (ALT) Q2 Earnings Beat Expectations but Remain Unprofi - GuruFocus
Q2 2026 Altimmune Inc Earnings Call Transcript - GuruFocus
Form 8K Altimmune Inc For: 12 August By Investing.com - Investing.com South Africa
Altimmune posts smaller-than-expected Q2 net loss per share - TradingView
Altimmune posts $22.8M Q2 net loss, $519M cash; advances pemvidutide Phase 3 and Phase 2 programs - TradingView
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - The Manila Times
Altimmune Reports $22.8 Million Q2 Loss and Advances Pemvidutide Trials - Quiver Quantitative
Altimmune (NASDAQ:ALT): What Could Today’s clinical evidence and program focus Update Reveal? - Kalkine Media
Altimmune Inc (ALT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Altimmune (ALT) Q2 Earnings Preview: Unpacking Valuation and Guru Ownership Signals - GuruFocus
Altimmune (ALT) Earnings Date and Reports 2026 $ALT - MarketBeat
Altimmune Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Weekly Recap: Altimmune (ALT) PERFORMA Phase 3 launch and Aug 12 results - TradingView
Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Altimmune, Inc. (ALT) options chain – Yahoo Finance - sg.finance.yahoo.com
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Altimmune to discuss its liver-treatment candidate Aug. 12 - Stock Titan
ALT Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday - marketbeat.com
알티뮨 (ALT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
알티뮨 주식 (ALT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GILL JOHN | Director |
Apr 06 '26 |
Buy |
3.41 |
9,200 |
31,350 |
21,700 |
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
1.80%
1.77%
자본화:
|
볼륨(24시간):